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Abstract
The proliferative stimulus of the epidermal growth
factor (EGF) in human epithelial cells is mediated by
its binding to the external domain of the EGF receptor
(EGF-R). The purpose of this study was to investigate
whether growth arrest of tumors treated with anti -EGF-
R MAb (EMD 55900) was dependent on EGF-R ex-
pression and distinct histopathologic criteria of those
neoplasms. Nine different adenocarcinomas, squamous
cell carcinomas and two neoplastic epithelial cell lines
(A431 and Detroit 562), which were characterized by
high EGF-R expression, were xenotransplanted onto
NMRI-nu/nu mice and treated with an anti -EGF-R
antibody (EMD 55900). Results revealed that EGF-R
expression and distinct histopathologic growth pat-
terns play an important role for the therapeutic effect of
the EGF-R antibody treatment. Tumors with high
epithelial cellularity and little connective tissue res-
ponded to EMD 55900 treatment to a greater degree of
growth reduction than tumors with lower cellularity.
These results will be helpful for evaluation of patients
who would benefit from tumor therapy with anti -EGF-R
antibody.
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Introduction
The proliferative stimulus of cytokines like epidermal growth
factor (EGF) is mediated by its binding to the extracellular
domains of a specific transmembrane receptor family.
These receptors are known as the c-erbB receptors, which
consist of at least the four members c-erbB-1 to c-erbB-4.
Binding of natural ligands like EGF or transforming growth
factor alpha (TGF- ) results in dimerization of these
receptors, whereby the formation of homo- and hetero-
dimers is described (reviewed in Ref. [1 ] ). Dimerization
results in cross- and/or autophosphorylation processes,
mediated by intracellular C- terminal tyrosine kinase resi-
dues. The phosphorylated and activated receptors are
recognized by specific proteins, which in return activate a
signaling cascade, the Ras–Raf–MEK kinase cascade,
resulting in recruitment and activation of transcription factors
[2-4]. However, erbB-2/erbB-3 heterodimers possess a
special role in this context due to the fact that erbB-3 is
kinase dead, has about six binding sites for PI-3 kinase,
and erbB-2 has no high affinity ligand. The formation of
these dimers is driven by neuregulins (NRG1- / and
NRG2- / ) as ligand [5,6 ].
Analyses of solid tumors revealed a correlation between
the 170-kDa transmembrane EGF receptor (c-erbB-1,
EGF-R) expression and histopathologic grading, whereby
tumors with low EGF-R expression showed a higher degree
of differentiation and correlate with an improved prognosis
for the patients [7,8 ]. EGF-R protein overexpression is
described for a variety of human malignancies, including
breast cancer, ovarian cancer, prostate cancer, non–small
cell lung cancer, head and neck cancer, and glioblastomas.
These findings define the EGF-R as a valuable target for
an antibody-mediated tumor therapy [9-11] and led to the
development of the EGF-R antibody EMD 55900 [12].
This monoclonal antibody binds to the extracellular domain
of EGF-R, close to the EGF binding domain, and does not
induce any tyrosine kinase activity on its own whereby
EMD 55900 binding inhibits receptor activation by natural
ligands thereby interrupting activation of downstream
signaling cascade activated by EGF or TGF-, respec-
tively [12,13].
This led to the perception that the therapeutic effect of
EMD 55900 in human breast cancer is dependent on
EGF-R protein expression levels of the tumor in general.
In a previous study, we were able to show a dependency
between EGF-R level and therapeutic effect of EMD
55900 for xenotransplanted breast cancer [14]. Actually,
breast cancers are known to have a relative low level of
EGF-R protein expression. In contrast, it was demonstrated
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that squamous cell carcinomas and some adenocarcino-
mas of different origins showed a much higher content of
EGF-R than breast cancer, whereby tumors of the cervix,
vulva, ovaries, pharynx/ larynx, and thyroid gland show up
to tenfold higher EGF-R content than breast cancer [14-
19]. The aim of this study was to demonstrate the
therapeutic effect of EMD 55900 with respect to growth
inhibition of human squamous cell carcinomas and
adenocarcinomas with high EGF-R content and to find




EMD 55900 is a murine lgG2a directed against the human
EGF-R and was first described by Murthy et al. [12 ]. The
humanized version of this antibody (EMD 72000) was used
for comparison.
All antibodies for this study were provided by E. Merck
(Darmstadt, Germany).
Animal Experiments
Xenotransplantation and tumor measurement Tumor speci-
mens of different origin of patients who were treated
between 1976 and 1990 in the University Hospital of
Frankfurt /Main, Germany were transplanted onto athymic
nude mice and kept as xenotransplants. Nine human
tumors and two solid specimens from a human vulva
carcinoma cell line (A-431) and a human larynx cell line
(Detroit 562) were transplanted subcutaneously as tissue
fragments of 2mm3 size onto 4- to 5-week-old nude mice.
The tumor growth in nude mice was measured with vernier
calipers weekly, and in case of A431, every 3 days. Tumor
area was calculated by multiplication of the greatest
diameter with the perpendicular diameter. Measurements
were taken once a week. Measurements of all tumors
within the group were represented by the mean value.
Mean values (square millimeters) were plotted against
time (days) post transplantation, resulting in growth
curves.
Treatment Protocol From all 11 tumors the individual growth
pattern of each tumor was examined in 14 to 21 animals, half
of them treated with EMD 55900 and the others with
phosphate-buffered saline (PBS; 0.15 M NaCl, 1.5 mM
NaH2PO4, 5 mM Na2HPO4, pH 7.4) to serve as control
group.
The treatment protocol started on day 0, which is the
day of first tumor measurement, 1 week after tumor
transplantation. According to our previous investigations
[14] 100 mg/kg of EMD 55900 in 0.45 ml PBS was
injected intraperitoneally into each mouse of the therapy
group. The control group received 0.45 ml PBS only. To
examine the therapeutic effect to tumors of larger
diameters, groups of seven animals were treated on day
12 or day x (x means the time when a tumor size of
about 70 mm2 was reached) with 100 mg/kg EMD 55900
for the cervical cancer (CV2) and the ovarian cancer
(OV2).
Histopathologic Examination
Tumors of the control group were carefully removed from
the subcutis and weighed. Afterwards each tumor was cut in
two parts, cystic fluid and necrosis were removed, and the
tumor was weighed again. One half was deep- frozen for the
EGF-R determination and the second half was fixed in 4%
phosphate-buffered formalin, dehydrated, and embedded in
paraffin. One section of each tumor was stained with
hematoxylin /eosin and another section was stained accord-
ing to Goldner [15] for examination of the connective tissue
content and necrosis.
Immunohistochemical Staining of CD31
Angiogenesis was determined by means of immunohis-
tochemical staining with CD31. Sections (3- to 4-m) were
deparaffinized and boiled five times for 3 minutes in a citric
buffer (10 mM citric acid, 10 mM sodium citrate, pH 6.0). Rat
anti -mouse CD31 (Clone nER-MP12, Dianova, Hamburg,
Germany) was diluted 1:10 in PBS and the tissues were
incubated for 1 hour at room temperature with primary
antibody. After washing with PBS the tissues were stained
with an anti - rat super sensitive AP-kit (Bio Genex (DCS),
Hamburg, Germany) and Fast Red, blocked with levamisole
(Bio Genex). Counterstaining was done with hematoxylin
according to Mayer for 1 minute. The results are expressed
in a semiquantitative fashion and with a score from 0 to 5,
where 0 means no CD31 detectable and 1 to 5 little to strong
staining.
EGF-R Quantitative Assay
Tissues obtained from excised tumors were dissected
and pulverized in liquid nitrogen by a microdismembrator (B.
Braun, Melsungen, Germany). The tissue powder was
suspended in lysis buffer (0.14 M NaCl, 2.6 mM KCl, 8 mM
Na2HPO4, 1.4 mM KH2P04 pH 7.4, 1% Tween-20) then
homogenized in a Teflon/glass homogenizer. Ultracentrifu-
gation for 1 hour at 100,000g yielded a supernatant
containing the cytosolic fraction and solubilized cell mem-
branes. Protein content was determined in the supernatant
by Bio-Rad protein assay (Biorad, Munich, Germany). The
solution was normalized to a protein content of 50 g/ml.
From each sample, 200 l in duplicate were used to measure
EGF-R concentration by ELISA (Immundiagnostik, Ben-
sheim, Germany).
Statistics
Mann–Whitney U tests were performed for statistical
evaluation of significant differences in growth patterns
between two study groups. Kruskal–Wallis test was used if
more than two groups were compared. Probabilities were
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considered significant at P0.05. Correlation coefficients
were determined using Spearman-Rho analysis.
Results
Growth Inhibition of Xenotransplanted Tumors by EMD
55900
To determine the growth inhibitory effects of the mono-
clonal antibody EMD 55900 in vivo, we established 11
different tumors as xenotransplants in athymic nude mice.
Nine tumors were obtained from spontaneously occurring
primary carcinomas, whereby five tumors were primary
squamous cell carcinomas of the uterine cervix and vulva
and four were primary adenocarcinomas from breast, thyroid,
and ovarian cancer (Table 1). The level of EGF-R protein
expression was determined in excised control tumors for
each experiment and ranged from 28 to 355 fmol /mg protein
with a median EGF-R expression of 112 fmol /mg protein
(Table 2). The animals were subjected to EMD 55900
antibody treatment at a single dose of 100 mg/kg body
weight applied intraperitoneally 7 days post transplantation.
All treated animals showed tumor growth inhibition by
antibody treatment in comparison to the corresponding
controls in the following observation period (Figure 1 ),
whereby the level of significance ranged from P=0.455 to
P<0.0001 (data reflected in Table 2) . However, there was
no significant correlation between increased EGF-R protein
expression and an increased sensitivity to antibody treatment
at the point of maximum growth reduction detectable.
Therapeutic Effect of EMD 55900 Correlates with Histo-
pathologic Parameters
To further elucidate parameters that influence therapeutic
effects of EMD 55900 we performed histopathologic exami-
nations of control tumors. Tumors were excised at the end of
the corresponding observation period and necrosis was
described macroscopically. Furthermore, the tumors were
weighed before and after dissection to determine the relative
level of liquid proportion (Table 2). The content of connective
tissue, degree of vascularization, and cellularity were
determined microscopically. All tumors exhibited a distinct
degree of central necrosis, whereby macroscopic features of
those tumors ( formation of cystic spaces, necrosis, con-
nective tissue), as well as the degree of vascularization
correlated with the relative proportion of connective tissue.
The CD31 score/degree of connective tissue ratio (RT)
revealed a factor that correlated with the therapeutic effect of
EMD 55900 (P=0.005, R=0.7, Spearman-Rho analysis).
Tumors with an RT0.1 showed an inhibition of tumor
Table 1. EGFR Content and Histological Criteria of the Tumor Specimens
Used.
Region Xenotransplant Passage Entity
Uterine cervix CV1 VII SCC
Uterine cervix CV2 X SCC
Uterine cervix CV3 XII SCC
Uterine cervix CV4 IX SCC
Ovarian OV1 XI Adenocarcinoma
Ovarian OV2 XI Adenocarcinoma
Vulva VU1 IX SCC
Breast BC5 CVII Adenocarcinoma
Thyroid TH1 VL Adenocarcinoma
Larynx Detroit 562 (ATCC;
No. CCL -138 )
VII SCC
Vulva A431 (ATCC;
No. CRL -1555 )
V SCC
Table 2. Histological Criteria in Correlation to the Effects of Anti -EGFR Therapy.
Tumor BC5 VU1 TH1 OV2 A431 Detroit 562 CV2 CV1 CV3 OV1 CV4
% Fluid ( cysts ) 32 27 13.5 0 39 16.5 0 0 0 0 0
% Necrosis 10–20 15 40 10 10 20 70 70 40 50–60 70–80
Description of necrosis fluid fluid soft medium fluid smeary medium soft firm gelatinous firm
smeary soft fluid soft
fluid smeary
Connective tissue (%) 10 0 40 20–30 5 20 20 20 30 10–20 20–30
EGFR ( fmol /mg ) 266 187 105 44 355 112 124 212 75 28 108
CD31 score 1 0 3 3 0 2 4 3 4 3 4
Maximum tumor reduction (%) 99,5 99,5 99 99 96 92 87 79 70 51 44
P< 0.0001 0.0001 0.0001 0.001 0.0001 0.0031 0.0001 0.008 0.0015 0.0001 0.455
RT 0.1 0 0.075 0.075 0 0.1 0.2 0.15 0.13 0.2 0.16
Fluid= liquefactive necrosis; Firm=coagulative necrosis; Others=mixed forms.
Figure 1. Relative growth curves of treated tumors divided through control
tumors from 11 xenotransplanted human tumors after single therapy with EMD
55900 (100 mg / kg i.p. on day of first tumor measurement [ day 0 ] ). The
tumors A431, BC5, VU1, TH1, OV2, Detroit 562, and CV2 show a complete
remission a few weeks following EMD 55900 application. The tumors OV1,
CV1, and CV3 show a 50% growth reduction 4 to 8 weeks after antibody
application whereas the tumor CV4 shows a growth reduction of 25% 9 weeks
after EMD 55900 treatment.
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growth of at least 92% (growth inhibition ranged from 99.5%
to 92.0%) whereas tumors with an RT>0.1 showed a
maximum growth inhibition of 87.0% (range: 44.0 to
87.0%) (P<0.001, Mann–Whitney U ). Figure 2 shows
representative histologic sections for two different carcino-
mas whereby the tumor BC5 had an RT of 0.1 and CV4 had
an RT of 0.16. Furthermore, the RT is also a factor to
determine the nature of necrotic tissue ( i.e., liquefactive and
coagulative necrosis), whereby an RT0.1 is correlated with
the description of a more liquid form of necrosis. These
results are reflected in growth characteristics of the
squamous cell carcinomas VU1 and CV4. The carcinoma
VU1 with an RT of 0.0 showed maximum growth inhibitory
effect to EMD 55900 treatment in contrast to CV4 with an RT
of 0.16. EGF-R protein expression of CV4 was comparable
to VU1 but CV4 showed nearly no response to antibody
treatment (Figure 3 ).
To further determine the therapeutic effects of EMD
55900 on tumors of different sizes, we used two represen-
tative tumors that represented the two observed types of
necrosis: CV2 (RT=0.2) and OV2 (RT=0.075). Three
therapeutic groups were formed: The first group was treated
on the day of first measurement (7 days post trans-
plantation), the second was treated on day 12 after first
measurement (mean tumor size was 20 mm2 in both
cases), and the third group was treated when mean tumor
size reached 70 mm2. Each group consisted of a minimum
of 16 transplanted tumors and EMD 55900 antibody was
given once at a constant dose of 100 mg/kg body weight.
The results confirm the influence of RT at all stages of
tumor establishment. The tumor OV2 with an improved
prognostic RT of 0.075 showed increased susceptibility to
EMD 55900 treatment and a prolonged period of tumor
growth inhibition at all stages of tumor establishment. In
contrast, the tumor CV2 showed no regression when tumor
size exceeded 50 mm2. Nevertheless, the duration of
growth arrest seemed to be constant ( for OV2 over 9
weeks and CV2 more than 5 weeks). After that period, in all
Figure 2. Typical comparison of two tumors with different RTs. Image of the
excised and sectioned tumor of xenotransplanted cervical cancer CV4 with an
RT of 0.16 shows a large area of coagulative necrosis ( upper left ).
Furthermore, CV4 shows a high degree of connective tissue in the
corresponding Goldner staining (middle left ) as well as a high degree of
vascularization ( lower left ) in CD31 staining. In contrast, tumor BC5
(RT=0.1 ) shows a central cyst ( drained, upper right ), a low content of
connective tissue (middle right ), and a low grade of vascularization ( lower
right ).
Figure 3. (A ) Growth curves of human cervical cancer CV4 with an EGF -R
content of 108 fmol /mg protein transplanted onto nude mice and treated with
a single dose of 100 mg /kg EMD 55900. The tumor is free of cysts, consists
approximately 80% necrosis and 20% to 30% connective tissue (RT=0.16 ).
Treatment with EMD 55900 revealed no significant growth reduction in
comparison to the corresponding controls (P=0.455, n=16 for each group,
Mann–Whitney U test ). (B ) Growth curve of human vulva cancer VU1 with an
EGF -R content of 187 fmol /mg protein transplanted onto nude mice and
treated with a single dose of 100 mg /kg EMD 55900. The tumor shows a
cystic growth (27% of tumor mass is fluid ), a very low content of connective
tissue, and 5% necrosis (RT=0 ). The therapeutic effect is a complete
remission 5 weeks after EMD 55900 treatment (P<0.0001, n=22 tumors in
control group and n=20 tumors in EMD 55900– treated group, Mann–
Whitney U test ).
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cases a low grade of tumor growth progression was
detectable (Figure 4 ).
Discussion
Growth factors and their receptors play an important role in
regulating the growth of malignant cells in vivo. Several
investigators have reported that overexpression of EGF-R in
a variety of tumors is associated with poor prognosis for the
patients [16,17]. The inhibitory effect of several anti–EGF-
R antibodies such as MAb C225 on tumor growth have been
extensively investigated in other tumor models. It has been
shown that treatment of cells with these MAbs leads to
inhibition of EGF-R downstream signaling, resulting in
accumulation of cells in G1 due to upregulation of p27KIP -1
and hypophosphorylation of retinoblastoma protein pathway
[18,19]. Treatment of a renal cell carcinoma cell line RCC
with MAb C225 in vitro showed a weaker effect than in vivo
xenograft model [20]. This supported the notion that
antitumor effect in mice is not only a blockade of endogenous
EGF. There might be an active influence of the immune
system of the mouse [21]. Among direct effects of tumor-cell
response, a variety of mechanisms of action of EMD 55900
are discussed, such as antibody-dependent cellular cyto-
toxicity (ADCC) by linking natural killer cells via Fc fragment
of the antibody and phagocytosis by macrophages [21].
Furthermore, recent studies demonstrated also the down-
regulation of secretion of neoangiogenic factors in response
to anti -EGF-R antibody treatment [22,23]. This might also
be a further mechanism in vivo, whereby EMD 55900 inhibits
neovascularization in tumors exhibiting low pretreatment
CD-31 score.
The present study was undertaken to assess the ability of
the anti–EGF-R monoclonal antibody EMD 55900 to inhibit
the growth of several human tumors with different EGF-R
protein expression in vivo. The results of this study
demonstrate that treatment with EMD 55900 inhibits the
growth of larynx/pharynx, thyroid, breast, vulva, ovarian, and
cervix carcinomas in athymic nude mice. Furthermore, we
were able to demonstrate that the in vivo tumor response to
EMD 55900 treatment is not only dependent of EGF-R
protein expression.
We found the CD31/connective tissue ratio is a crucial
factor for the prediction of a therapeutic effect of EMD 55900
in tumors with high EGF-R expression. Interestingly, we
found that tumors exhibiting liquefactive forms of necrosis
were more susceptible to antibody therapy. In contrast,
tumors showing coagulative forms of necrosis were more
resistant to the treatment. Our previous investigations found
a strong correlation of EGF-R protein expression and
response to EMD 55900 treatment of breast cancer, ranging
from no effect at EGF-R-negative tumors to complete
remission of tumors highly overexpressing EGF-R [14]. In
contrast to this previous study, we investigated only EGF-
R-overexpressing tumors and found that the cellular
pattern and its histogenetic nature was significant in terms
of tumor treatment. The precise mechanism of these
findings remains to be further elucidated. Potentially, a
reason for less response in stroma-rich tumors might be
a paracrine stimulation of non–EGF-R growth factor
systems like HRG-ErbB2/3, FGF, and PDGF [24,25].
We demonstrated that cervical, ovarian, breast, larynx/
pharynx, and thyroid carcinomas that express functional
EGF-R are responsive to antiproliferative activity of EMD
55900. Specific histopathologic features seemed of
importance in this context, whereby highly cellular tumors
seemed to be most responsive. The treatment with EMD
55900 has been documented to be a promising approach
for the treatment of certain cancers. Additionally, CD31/
connective tissue ratio could be a promising tool to
improve the prediction of therapeutic value by monoclonal
antibody therapy.
Figure 4. (A ) Growth curve of cervical cancer CV2 (RT=0.2 ) after single
therapy with 100 mg /kg EMD 55900 on the day of first tumor measurement
(d0 ), 12 days after first tumor measurement ( d12 ), and when the tumor
has reached a mean size of approximately 70 mm2 (dx ). Therapy on day 0
(d0 ) leads to an immediate stop of tumor growth for about 4 weeks followed
by a remarkable slower tumor growth in comparison to the control. Therapy
on day 12 causes a tumor regression for about 4 weeks and afterwards no
detectable tumor growth for about 5 weeks. Therapy on day x (dx ), in this
case 4 weeks after transplantation, leads to a stop of proliferation for more
than 5 weeks. The control group, dx and d12, represent 14 tumors,
therapeutic group (do ) represents n=16 tumors. (B ) Growth curve of
ovarian cancer OV2 (RT=0.075 ) after single therapy with 100 mg /kg EMD
55900 on the day of first tumor measurement (d0 ), 12 days after first tumor
measurement ( d12 ) and when the tumor has reached a mean size of
approximately 70 mm2 (dx ). Therapy on day 0 (d0 ) leads to an immediate
stop of tumor growth for about 10 weeks followed by a remarkable slower
tumor growth in comparison to the control. Therapy on day 12 (d12 ) causes
complete tumor regression for 15 weeks. Therapy on day x (dx ), in this
case 6 weeks after transplantation, leads to a tumor regression of about
50% for 7 weeks. The control group represents n=18 tumors, d0 and d12
therapeutic groups represent n=16 tumors, and dx therapeutic group
represents n=12 tumors.
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